Product Details
| Product Name:
NMS-P515 |
CAS No.:
1262395-13-0 |
| Supply Ability:
10g |
Release date:
2025/10/27 |
Product Introduction
Bioactivity
| Name | NMS-P515 |
| Description | NMS-P515 is an effective, orally active, and stereospecific PARP-1 inhibitor (Kd: 16 nM and an IC50: 27 nM (in Hela cells)). It has anti-tumor activity. |
| In vivo | NMS-P515 (80 mg/kg; p.o.; 12 days) shows effective antitumor activity in mouse models based on pancreatic cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | PARP-1 | NMS-P-515 | NMS-P515 | NMSP515 | NMS-P 515 | NMS P515 |
| Inhibitors Related | Niraparib tosylate monohyrate | VPC-70063 | 3-Aminobenzamide | XAV-939 | Niraparib | Chlorin E6 | AZ9482 | NU1025 | RMC-7977 | Olaparib | Benzamide | OUL35 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
-
-
CAS:1403679-33-3
$3700.00 / 100mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$97.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-11-10 |
|
|
$39.00/2mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-10 |
|
|
$100.00/1Kg/Bag |
|
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-09-13 |